A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

NCT01106352 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastases
Castration-Resistant Prostate Cancer

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)
DRUG: Docetaxel

Sponsor

Bayer